3-氰基-4-羟基苯甲酸 | 70829-28-6

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氰基-4-羟基苯甲酸
• 中文别名: 3-腈基-4-羟基苯甲酸
• 英文名称: 3-cyano-4-hydroxybenzoic acid
• CAS: 70829-28-6
• 化学式: C₈H₅NO₃
• 分子量: 163.133
• InChiKey: KUCSFDLSLAVLBY-UHFFFAOYSA-N

物化性质

• 熔点：
  265-266 °C
• 沸点：
  392.4±37.0 °C(Predicted)
• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下应保持干燥且密封存储。

反应信息

• 作为反应物：
  描述：

  3-氰基-4-羟基苯甲酸 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 生成 3-cyano-4-hydroxybenzoic acid hydrazide
  参考文献：
  名称：

  Human glucagon receptor antagonists based on alkylidene hydrazides

  摘要：

  A series of alkylidene hydrazide derivatives containing an alkoxyaryl moiety was optimized. The resulting hydrazide-ethers were competitive antagonists at the human glucagon receptor. Pharmacokinetic experiments showed fast clearance of most of the compounds tested. A representative compound [4-hydroxy-3-cyanobenzoic acid (4-isopropylbenzyloxy-3,5-dimethoxy-methylene)hydrazide] with an IC50 value of 20 nM was shown to reduce blood glucose levels in fasted rats. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00819-8
• 作为产物：
  描述：

  4-羟基-3-碘苯甲酸甲酯 在 copper(l) cyanide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 3-氰基-4-羟基苯甲酸
  参考文献：
  名称：

  [EN] FTO INHIBITORS
  [FR] INHIBITEURS DE FTO

  摘要：

  Provided are a compound of Formula (I) as an FTO inhibitor with improved and selective FTO inhibition, a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.

  公开号：

  WO2024022491A1

文献信息

• [EN] S1P RECEPTORS MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010042998A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

  该发明涉及具有S1P受体调节活性的新化合物，最好具有对癌细胞和其他细胞类型具有凋亡活性和/或抗增殖活性。此外，该发明涉及包含该发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如癌症。该发明的另一个方面涉及使用包含该发明中至少一种化合物的药物制备药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如癌症。
• Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors
  作者：Dingding Gao、Nan Jin、Yixian Fu、Yueyue Zhu、Yujie Wang、Ting Wang、Yuehong Chen、Mingming Zhang、Qiang Xiao、Min Huang、Yingxia Li

  DOI：10.1016/j.ejmech.2021.113333

  日期：2021.4

  The cumulative evidence supports STAT3, a transcriptional mediator of oncogenic signaling, as a therapeutic target in cancer. The development of STAT3 inhibitors remain an active area of research as no inhibitors have yet to be approved for cancer treatment. In a continuing effort to develop more potent STAT3 inhibitors based on our previously identified hit compound 16w, a series of benzothiazole

  累积的证据支持STAT3（一种致癌信号的转录介质）作为癌症的治疗靶标。STAT3抑制剂的开发仍然是一个活跃的研究领域，因为尚未批准任何抑制剂用于癌症治疗。在基于我们先前确定的命中化合物16w不断开发更有效的STAT3抑制剂的过程中，设计，合成和生物学评估了一系列在STAT3的SH2结构域具有独特结合模式的苯并噻唑衍生物。值得注意的是，化合物B19对IC 50表现出优异的针对IL-6 / STAT3信号通路的活性通过萤光素酶报告基因测定法测定的值低至0.067μM。此外，多种化合物显示出对MDA-MB-468和JAK2突变HEL细胞系有效的抗增殖活性。使用蛋白质印迹法的进一步生化研究表明，B19阻断了Tyr 705和Ser 727处STAT3的磷酸化，从而抑制了STAT3介导的c-MYC和MCL-1基因表达。同时，它在MDA-MB-468和HEL细胞系中诱导癌细胞G2 / M期阻滞和凋亡。最
• 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Fujii Akihito

  公开号：US20120059012A1

  公开（公告）日：2012-03-08

  Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 is 1: a C 3-8 cycloalkyl C 1-4 alkyl group, 2: a C 7-14 aralkyl group, in which the aryl moiety thereof is optionally substituted with the same or different 1 to 3 groups selected from the group consisting of: (a) halogen, (b) C 1-4 alkyl, which is optionally substituted with 1 to 3 fluorine atoms, (c) C 1-4 alkoxy, which is optionally substituted with 1 to 3 fluorine atoms, and (d) C 1-4 alkylcarbonyl, which is optionally substituted with C 1-4 alkoxy, 3: a five- to ten-membered heteroaryl-C 1-4 alkyl group, in which the heteroaryl moiety thereof is optionally substituted with the same or different 1 to 3 groups selected from the group consisting of: (a) halogen, and (b) C 1-4 alkyl, or 4: a C 6-10 aryl C 2-6 alkenyl group; and R 2 is a cyano group or a nitro group.

  揭示了由化学式（I）表示的化合物或其药学上可接受的盐：其中R1是1：C3-8环烷基C1-4烷基基团，2：C7-14芳基烷基基团，其中其芳基部分可选择性地取代为来自以下组成的1至3个相同或不同的基团：(a)卤素，(b)C1-4烷基，可选择性地取代为1至3个氟原子，(c)C1-4烷氧基，可选择性地取代为1至3个氟原子，和(d)C1-4烷基羰基，可选择性地取代为C1-4烷氧基，3：五元至十元杂芳基-C1-4烷基基团，其中其杂芳基部分可选择性地取代为来自以下组成的1至3个相同或不同的基团：(a)卤素，和(b)C1-4烷基，或4：C6-10芳基C2-6烯基基团；和R2是氰基或硝基基团。
• [EN] 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS<br/>[FR] DÉRIVÉS DE 4-((2-HYDROXY-3-MÉTHOXYBENZYL)AMINO)BENZÈNESULFONAMIDE COMME INHIBITEUR DE LA 12-LIPOXYGÉNASE
  申请人：EASTERN VIRGINIA MED SCHOOL

  公开号：WO2015054662A1

  公开（公告）日：2015-04-16

  Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3- methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells. The compounds can also be used in methods for treating or preventing a 12- lipoxygenase mediated disease or disorder.

  人类脂氧合酶（LOXs）是一类含铁酶的家族，参与催化多不饱和脂肪酸的氧化，提供相应的生物活性羟基二十碳四烯酸（HETE）代谢产物。这些花生四烯酸信号分子参与许多生理反应，如血小板聚集、炎症和细胞增殖。血小板型12-（S）-LOX（12-LOX）因其在皮肤疾病、糖尿病、血小板止血、血栓形成和癌症中的已知作用而特别引起关注。本文揭示了基于4-（（2-羟基-3-甲氧基苯基）氨基）苯磺酰胺骨架的鉴定和药物化学优化。这些化合物对12-LOX具有纳摩尔级的效力，并且对相关的脂氧合酶和环氧合酶具有良好的选择性。除了具有良好的ADME性质外，这些化合物还可以抑制PAR-4诱导的人类血小板聚集和钙离子动员，并减少小鼠/人类β细胞中的12-HETE。这些化合物还可以用于治疗或预防12-脂氧合酶介导的疾病或紊乱的方法。
• [EN] GLUCAGON ANTAGONISTS/INVERSE AGONISTS<br/>[FR] ANTAGONISTES/AGONISTES INVERSES DU GLUCAGON
  申请人：NOVO NORDISK AS

  公开号：WO1999001423A1

  公开（公告）日：1999-01-14

  Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof. The compounds act to antagonize the action of the glucagon peptide hormone.

  非肽化合物包含一个中心肼基结构，并且其合成方法。这些化合物作用是拮抗胰高血糖素肽激素的作用。